Wells Fargo raises Kymera Therapeutics price target to $151
Wells Fargo raised its Kymera Therapeutics price target to $151.00 per share from $116.00.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.